Axsome Therapeutics Presents Data from Multiple Programs at

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,

Related Keywords

New York , United States , Florida , Miami Beach , Toronto , Ontario , Canada , American , Roger Mcintyre , Jeffrey Cummings , Harryl Smith , Andrew Muzyk , Darren Opland , David Gozal , Mark Jacobson , Department Of Brain Health , Axsome Therapeutics Inc , Drug Administration , University Of Toronto , Nasdaq , Corporate Communications , Development Program , Department Of Child Health , American Society Of Clinical Psychopharmacology , World Trade Center , University Of Missouri , Clinical Psychopharmacology , Annual Meeting , Improving Anhedonia , Interest Activity Symptoms , Associated Improvements , Major Depressive , Associate Professor , Medical Education , Clinical Profile , Treating Alzheimer , Disease Agitation , Results From The Phase , Vice Chair , Solriamfetol Improves Cognitive Performance , Preclinical Models , Sleep Apnea , Randomized Placebo Controlled Study , Sleep Apnea Participants , Endowed Chair , Child Health , Breakthrough Therapy , Prescribing Information , Boxed Warning , Axsome Therapeutics ,